Radius Recycling Inc (NQ: RDUS )

19.52 -0.45 (-2.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Radius Recycling Inc

< Previous 1 2 3 4 Next >
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
FDA Accepts Menarini Group and Radius Health's Filing Under Priority Review For Breast Cancer Candidate
The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ: RDUS) New Drug Application (NDA) for the lead asset elacestrant in patients with ER+/HER2-... 
Via Benzinga
RADIUS HEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Radius Health, Inc. - RDUS
From Kahn Swick & Foti, LLC
Via Business Wire
Velan-Repertoire to Withdraw Director Nominations Due to Pending Sale of Radius Health
From Velan-Repertoire Group
Via Business Wire
Short Volatility Alert: Radius Health, Inc.
On Monday, shares of Radius Health, Inc. (NASDAQ: RDUS) experienced volatile short activity. After the activity, the stock price went up +0.69% to $10.18. The overall sentiment for RDUS has been... 
Via Benzinga
4 Analysts Have This to Say About Radius Health
Analysts have provided the following ratings for Radius Health (NASDAQ:RDUS) within the last quarter: 
Via Benzinga
Bone Health Focused Radius Health Goes Private In $890M Deal
Via Benzinga
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Velan-Repertoire Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square Capital
From Velan Capital Investment Management LP and Repertoire Partners LP
Via Business Wire
Recap: Radius Health Q1 Earnings
Radius Health (NASDAQ:RDUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown... 
Via Benzinga
RADIUS HEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Radius Health, Inc. - RDUS
From Kahn Swick & Foti, LLC
Via Business Wire
RDUS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Radius Health, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Velan-Repertoire Releases Detailed Presentation on the Need for Board Change at Radius Health and Sends Letter to Stockholders
From Velan Capital Investment Management LP and Repertoire Partners LP
Via Business Wire
63 Biggest Movers From Yesterday
Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the... 
Via Benzinga
Rubric Capital Management Sends Letter to Radius Health Board of Directors
From Rubric Capital Management LP
Via Business Wire
Velan-Repertoire Responds to Misleading Characterizations by the Radius Board
From Velan-Repertoire Group
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2022
Upgrades 
Via Benzinga
Velan-Repertoire Group Files Definitive Proxy Materials in Connection With Radius Health 2022 Annual Meeting
From Velan-Repertoire Group
Via Business Wire
Radius Health's Return On Capital Employed Insights
Radius Health (NASDAQ:RDUS) brought in sales totaling $43.16 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 17.27%, resulting in a loss of $18.28 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
Via Benzinga
Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer
The Menarini Group and Radius Health Inc's (NASDAQ: RDUS) data from the phase 3 EMERALD trial evaluating elacestrant for ER+/HER2- advanced or metastatic breast cancer were published in the Journal of... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Radius Health (NASDAQ:RDUS) stock moved upwards by 18.8% to $6.94 during Thursday's after-market session. The company's market cap stands at $330.1 million. 
Via Benzinga
How To Attend Radius Health Q1 2022 Earnings Conference Call
Radius Health (NASDAQ:RDUS) will host a conference call at 08:30 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Radius Health (RDUS) Conference Call Follow this link to access... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Avidity Biosciences (NASDAQ:RNA) s... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Aptorum Group (NASDAQ:APM) stock m... 
Via Benzinga
FDA Approves Update On Radius Health's Tymlos label
The FDA has approved updates to Radius Health Inc's (NASDAQ: RDUS) Tymlos label, including removing the boxed warning regarding the risk of osteosarcoma, a... 
Via Benzinga
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.